R&D News | pharmaphorum

News

Pfizer, Metsera $10bn marriage back on after rough patch

Pfizer has won the battle for obesity drug developer Metsera, after rival Novo Nordisk said that it would not increase its bid above $10bn.

News

Intellia shares fall after hospitalised CRISPR patient dies

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.

News

Braveheart, AAVantgarde rounds head recent biofinancings

Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

News

Lilly reports 20% weight loss with amylin-targeting drug

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

News

Novo Nordisk fights back with oral GLP-1 data in obesity

Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.

News

Pfizer said to have matched Novo's $10bn bid for Metsera

The battle for obesity drug developer Metsera rumbles on, with Pfizer reported to have now matched Novo Nordisk's $10 billion offer.

Pfizer, Metsera $10bn marriage back on after rough patch

Intellia shares fall after hospitalised CRISPR patient dies

Braveheart, AAVantgarde rounds head recent biofinancings

Lilly reports 20% weight loss with amylin-targeting drug

Novo Nordisk fights back with oral GLP-1 data in obesity

Pfizer said to have matched Novo's $10bn bid for Metsera

US pharma tariffs of up to 100% finalised by Trump

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks